Better Therapeutics to Host Call Detailing Promising Results from Pivotal Clinical Trial for Type 2 Diabetes Digital Therapeutics
March 23 2022 - 7:00AM
Business Wire
Leading Medical Experts to Discuss Top-Line
Results Showing Significant Glycemic Improvement Using BT-001
Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX),
a prescription digital therapeutics company developing nutritional
cognitive behavioral therapy (nCBT) to address the root causes of
cardiometabolic diseases, today announced that it will hold a call
this Friday, March 25, to provide a deeper look at the results from
the company’s pivotal clinical trial for BT-001, a prescription
digital therapeutic for type 2 diabetes.
Last week, the company shared the primary endpoint results from
this milestone trial, which demonstrated clinically meaningful and
statistically significant improvement in A1c, a measure of sugar in
the blood, between the intervention and control groups (difference
of -0.4%; p<0.001) and no device or study-related adverse effect
after 90 days. The company also indicated that it plans to file a
de novo classification request with the FDA following trial
completion in Q2 2022.
WHEN: Friday, March 25, 2022 – 1:00 PM ET
WHAT: The call will be hosted by Rahul Rakhit, an equity
research analyst with LifeSci Capital, and will provide an
opportunity to take a deeper look at the clinical significance of
this safety and efficacy data and will provide additional context
for how BT-001 may be used in the current treatment paradigm. It
will also cover expectations and considerations for the 180-Day
readout of the study data in Q2, as well as the upcoming Real World
Evidence study in Q3.
WHO: Dr. Mark Berman serves as Better’s Chief Medical
Officer. Previously, he practiced as an internal and lifestyle
medicine physician at One Medical. Dr. Berman received his M.D.
from Yale. He completed residency at Harvard’s Brigham and Women’s
Hospital and a clinical research fellowship at University of
California, San Francisco. He has also served as a director of the
American College of Lifestyle Medicine
Dr. Marc Bonaca is a Cardiologist and Vascular Medicine
Specialist who serves as the Executive Director of CPC Clinical
Research and CPC Community Health which is an Academic Research
Organization created by and affiliated with the University of
Colorado Anschutz Medical Campus. Dr. Bonaca has extensive
experience in the design and conduct of large multicenter
randomized clinical trials as well as analyses in registries and
real-world datasets. His key areas of interest include patients
with peripheral artery disease, polyvascular disease and diabetes
with a focus on the breadth of risk including ischemic limb
outcomes, microvascular complications, and major adverse
cardiovascular events. Other clinical research interests include
the evaluation of novel antithrombotic, lipid lowering and glucose
lowering drugs, and the use of established and novel biomarkers or
risk prediction and personalization of therapy. He is a member of
the Society of Vascular Medicine, American College of Cardiology
(ACC) and American Heart Association (AHA). He currently serves on
the ACC PVD Leadership Council and is an associate editor for the
Vascular Medicine.
WHERE: To attend the call, please email Robert Fromberg
(rfromberg@lifescicapital.com) to register and receive the dial-in
information. Additionally, a replay link will be available
following the call at investors.bettertx.com.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT)
company developing a novel form of cognitive behavioral therapy to
address the root causes of cardiometabolic diseases. The company
has developed a proprietary platform for the development of
FDA-regulated, software-based solutions for type 2 diabetes, heart
disease and other conditions. The cognitive behavioral therapy
delivered by Better Therapeutics’ PDT is designed to enable changes
in neural pathways of the brain so lasting changes in behavior
become possible. Addressing the underlying causes of these diseases
has the potential to dramatically improve patient health while
lowering healthcare costs. Better Therapeutics clinically validated
mobile applications are intended to be prescribed by physicians and
reimbursed like traditional medicines.
For more information visit: bettertx.com
Forward-Looking Statements
Certain statements made in this press release are
"forward-looking statements" within the meaning of the safe harbor
provisions under the United States Private Securities Litigation
Reform Act of 1995. Forward-looking statements are typically
identified by words such as “plan,” “believe,” “expect,”
“anticipate,” “intend,” “outlook,” “estimate,” “forecast,”
“project,” “continue,” “could,” “may,” “might,” “possible,”
“potential,” “predict,” “should,” “would” and other similar words
and expressions, but the absence of these words does not mean that
a statement is not forward-looking. The forward-looking statements
in this press release include, but are not limited to, statements
regarding the timing and results of the ongoing trial of BT-001 in
patients with type 2 diabetes, Better Therapeutics’ plans regarding
FDA submissions, expectations related to the potential benefits of
BT-001 and CBT and their potential treatment applications, Better
Therapeutics’ plans regarding the research and advancement of its
product candidates for additional treatments, expectations related
to the interest of healthcare providers and payers in PDTs and
legislative developments affecting PDTs and the outcome of such
developments, among others. These forward-looking statements are
based on the current expectations of the management of Better
Therapeutics and are inherently subject to uncertainties and
changes in circumstances and their potential effects and speak only
as of the date of such statement. There can be no assurance that
future developments will be those that have been anticipated. These
forward-looking statements involve a number of risks, uncertainties
or other assumptions that may cause actual results or performance
to be materially different from those expressed or implied by these
forward-looking statements including: risks related to Better
Therapeutics’ business, such as the willingness of the FDA to
authorize PDTs for commercial distribution and insurance companies
to reimburse their use, market acceptance of PDTs, the risk that
the results of previously conducted studies will not be repeated or
observed in ongoing or future studies involving our product
candidates and other risks and uncertainties included under the
header “Risk Factors” in the definitive proxy statement/prospectus
filed by us on October 12, 2021.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220323005268/en/
Better Therapeutics Press Contact: Ryan McKenna at Real
Chemistry rmckenna@realchemistry.com
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Jul 2023 to Jul 2024